SCHEMBL369035

SCHEMBL369035

CC(C)N1CCN(c2cc(N3CCN(C)CC3)cn3c(=O)c(OCc4ccccc4)c(C(=O)NCc4ccc(F)cc4)nc23)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.38
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTR7 P34969 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
CTNNB1 P35222 1/20 0.35
TCF7L2 Q9NQB0 1/20 0.35
HTR6 P50406 1/20 0.35
KDM1A O60341 2/20 0.35
SIRT6 Q8N6T7 1/20 0.35
AURKA O14965 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070433 0.91 TP53 (0.37) KMT2ASMN1; SMN2TP53MAPTGAA
SCHEMBL367788 0.87 LMNA (0.40) SCDMEN1MAPK1KMT2AHSD17B10
SCHEMBL368069 0.87 KCNH2 (0.40) SCDMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL371044 0.87 MAPK1 (0.39) MEN1MAPK1KMT2AHSD17B10LMNA
SCHEMBL369910 0.84 TP53 (0.39) SCDHSD17B10HTR7SMN1; SMN2TP53
SCHEMBL367233 0.84 TP53 (0.39) MEN1MAPK1KMT2AHSD17B10SMN1; SMN2
SCHEMBL368655 0.82 HTR6 (0.43) MEN1MAPK1KMT2AHSD17B10SMN1; SMN2
SCHEMBL12505473 0.81 SCD (0.39) SCDMEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL368656 0.81 SMN1; SMN2 (0.40) SMN1; SMN2TP53LMNAMAPTL3MBTL1
SCHEMBL367968 0.80 TP53 (0.42) MEN1KMT2ASMN1; SMN2TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 SCD 3726/4885MEN1 4041/4885MAPK1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.